Posted by Michael Wonder on 13 Oct 2020
PMV Pharma granted FDA fast track designation of PC14586 for the treatment of advanced cancer patients that have tumours with a p53 Y220C mutation
13 October 2020 - PMV Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to its lead product candidate PC14586, for the treatment of cancer patients with locally advanced or metastatic solid tumours that have a p53 Y220C mutation.
There are currently no FDA approved medicines that target the p53 Y220C mutation.
PMV Pharma plans to conduct a Phase 1/2 open-label, multi-centre study to assess the safety, tolerability, pharmacokinetics, and anti-tumour activity of PC14586 in adult patients with a p53 Y220C mutation in locally advanced or metastatic solid tumours.
